China Abdominal Stent Graft System Market Size, Share, Trends and Forecasts 2032

Key Findings

• The China Abdominal Stent Graft System Market is expanding due to rising incidence of abdominal aortic aneurysm (AAA) and increasing preference for minimally invasive endovascular repair.
• EVAR procedures are gaining share over open surgical repair because of reduced hospitalization time, lower perioperative risk, and faster recovery outcomes.
• Continuous improvements in device conformability, sealing performance, and delivery system profile are improving suitability for complex anatomies in China.
• Hospitals are prioritizing low-profile, flexible stent graft platforms to support iliac access limitations and tortuous aortic pathways.
• Fenestrated and branched stent graft adoption is increasing for juxtarenal and complex AAA cases, supporting premium segment growth.
• Long-term surveillance needs and reintervention risk are shaping physician choice toward durable fixation and proven clinical evidence.
• Reimbursement policies, center-of-excellence expansion, and trained vascular specialists are improving procedural volumes in China.
• Device costs, regulatory approvals, and anatomy-driven eligibility constraints remain the key barriers to broader penetration.

China Abdominal Stent Graft System Market Size and Forecast

The China Abdominal Stent Graft System Market is projected to grow from USD 2.35 billion in 2025 to USD 4.15 billion by 2032, registering a CAGR of 8.5% during the forecast period. Growth is driven by increasing screening and diagnosis of AAA, higher procedural preference for endovascular aneurysm repair, and expanding availability of advanced stent graft configurations for challenging anatomies. Demand is also supported by aging populations and growing vascular disease burden that increases the treated patient pool. As hospitals expand minimally invasive vascular programs, the installed base of EVAR-capable cath labs and hybrid ORs improves access to stent graft procedures. Premium-priced fenestrated and branched solutions are raising average selling prices and value per case. The market is expected to expand steadily across China through 2032 as procedural confidence and clinical adoption continue to strengthen.

Introduction

Abdominal stent graft systems are implantable endovascular devices used to treat abdominal aortic aneurysms by excluding the aneurysm sac from systemic blood flow. These systems are delivered via catheter-based approaches through femoral or iliac access and deployed inside the aorta to create a new conduit for blood flow. In China, abdominal stent graft systems are most commonly used for infrarenal AAA via standard EVAR, while complex anatomies may require fenestrated or branched designs to preserve renal and visceral artery perfusion. Typical system components include the main body stent graft, iliac limb extensions, delivery catheters, and sealing/fixation mechanisms. Compared to open repair, endovascular approaches reduce operative trauma, shorten hospital stays, and improve near-term recovery. As vascular care shifts toward minimally invasive pathways, abdominal stent graft systems remain central to AAA management protocols.

Future Outlook

By 2032, the abdominal stent graft system market in China will increasingly shift toward broader eligibility coverage through more conformable designs, lower-profile delivery systems, and expanded options for complex and short-neck anatomies. Fenestrated and branched platforms will grow faster as physician experience increases and device planning workflows improve. Integration of advanced imaging, 3D planning, and intraoperative guidance will reduce sizing errors and improve procedural outcomes. Device manufacturers will focus on reducing endoleak rates, improving sealing in challenging anatomies, and enhancing long-term durability to minimize reinterventions. Hospital procurement will increasingly prioritize platforms with strong clinical evidence, reliable supply, and comprehensive physician training support. Overall, the market will evolve toward precision EVAR with higher anatomical coverage and improved lifecycle performance across China.

China Abdominal Stent Graft System Market Trends

• Rising Shift Toward Low-Profile and Highly Trackable Delivery Systems
  Stent graft developers in China are prioritizing low-profile delivery systems to improve access in patients with smaller or diseased iliac arteries. Reduced sheath size decreases access complications and broadens eligibility for minimally invasive treatment. Enhanced trackability and flexibility support navigation through tortuous aortic and iliac anatomy with fewer procedural delays. Improved pushability and controlled deployment mechanisms strengthen placement accuracy and reduce malposition risk. These advances support wider EVAR adoption in older and higher-risk patient populations where access limitations are common. As more centers standardize EVAR protocols, low-profile platforms are becoming a key procurement criterion.

• Growing Adoption of Fenestrated and Branched Stent Grafts for Complex AAA
  Complex AAA cases in China, including juxtarenal and pararenal aneurysms, are increasingly being treated using fenestrated and branched stent graft systems. These devices allow preservation of renal and visceral perfusion while expanding the treatable anatomy range beyond standard infrarenal EVAR. Improved pre-procedure planning software and imaging workflows are reducing case complexity and supporting more predictable outcomes. Physician familiarity and specialized center capability are increasing, enabling higher procedural volumes for complex repairs. Premium pricing and higher device content per case are raising the overall market value contribution from this segment. This trend is strengthening advanced product pipelines and accelerating innovation in branch geometry and sealing designs.

• Increased Focus on Reducing Endoleaks and Reintervention Rates
  Endoleaks remain a major clinical concern in China and are driving continued improvements in sealing zones, fixation methods, and graft material engineering. Manufacturers are optimizing proximal sealing rings, fixation barbs, and conformable graft fabrics to improve apposition in irregular neck anatomies. Enhanced limb designs are also improving iliac sealing and reducing limb occlusion or kinking risks. Clinical practice is increasingly guided by long-term outcomes, making durability and post-implant surveillance performance critical selection factors. Devices with stronger evidence on low reintervention rates are gaining preference in high-volume vascular centers. This trend is driving product differentiation around long-term stability, sealing reliability, and anatomical adaptability.

• Expansion of Imaging, 3D Planning, and Procedure Guidance Ecosystems
  EVAR programs in China are increasingly integrating advanced imaging, sizing tools, and 3D planning systems to improve device selection and procedural precision. Pre-operative planning helps optimize stent graft sizing, landing zone selection, and limb configuration to reduce complications. Intraoperative guidance technologies support accurate deployment and minimize contrast usage, improving safety for patients with renal impairment. Better visualization improves performance in complex anatomies and reduces procedure time variability across operators. Device companies are increasingly offering bundled planning support and training services to drive consistent outcomes. This trend is making workflow integration and digital planning capability a growing differentiator for stent graft platforms.

• Hospital Consolidation of Vascular Programs and Growth of Centers of Excellence
  In China, more hospitals are consolidating AAA repair into specialized vascular programs with dedicated teams and hybrid OR capabilities. Centers of excellence drive higher procedural volumes, stronger outcomes, and better adoption of advanced stent graft technologies. Concentrated expertise improves complex case capability, supporting uptake of fenestrated and branched systems. These centers also strengthen procurement standardization, often selecting a smaller set of preferred platforms to streamline training and inventory management. As referral networks grow, the treated patient pool expands and procedural confidence increases across regions. This trend supports consistent market growth through expanded capacity, improved access, and structured care pathways.

Market Growth Drivers

• Rising AAA Prevalence and Improved Screening and Diagnosis Rates
  Aging demographics and cardiovascular risk factors in China are increasing the prevalence of abdominal aortic aneurysms. Improved screening programs and broader diagnostic imaging utilization are identifying more AAA cases earlier. Earlier detection expands the treatable patient population and increases elective procedure volumes versus emergency repair. Elective EVAR procedures typically have better outcomes and encourage wider adoption among clinicians and hospitals. As awareness grows, referral pathways become more structured and consistent, supporting stable procedure growth. This clinical epidemiology shift is a foundational driver of demand for abdominal stent graft systems.

• Preference for Minimally Invasive EVAR Over Open Surgical Repair
  Hospitals and clinicians in China increasingly prefer EVAR due to lower perioperative morbidity and shorter recovery time compared to open repair. Reduced ICU requirements and shorter length of stay improve hospital throughput and cost efficiency. Patients also favor minimally invasive options, improving procedure acceptance rates and reducing postponement. EVAR enables treatment of high-risk patients who may not be suitable candidates for open surgery. The expanding capability of endovascular programs is increasing procedural volumes across both large hospitals and specialized vascular centers. This ongoing procedural shift directly drives demand for stent graft systems.

• Technology Advancements Expanding Eligibility for Complex Anatomies
  Innovation in device design is expanding the eligible patient pool in China by addressing short necks, angulated anatomy, and challenging iliac access. More conformable stent grafts improve apposition and sealing in irregular aortic anatomy. Lower-profile delivery and improved limb flexibility increase feasibility in patients with vascular disease and calcification. Fenestrated and branched systems further expand treatment to juxtarenal and complex AAA cases. As device options broaden, more patients can receive endovascular repair rather than surveillance or open surgery. This eligibility expansion is a major growth engine for the market.

• Growth of Hybrid OR Infrastructure and Vascular Specialist Capacity
  Investment in hybrid operating rooms and endovascular suites in China is increasing procedural capacity for AAA repair. These facilities enable advanced imaging, precise deployment, and better management of complex cases. Expansion of trained vascular surgeons and interventional specialists increases adoption across a wider hospital base. Standardized EVAR training programs and proctorship models improve outcomes and reduce learning curve barriers. Better infrastructure also supports post-procedure monitoring and follow-up, strengthening long-term patient management. Capacity expansion across facilities and personnel directly supports market growth.

• Reimbursement Support and Clinical Evidence Strengthening Procurement Confidence
  Reimbursement pathways and clinical guidelines in China increasingly support EVAR as a standard-of-care approach for eligible AAA patients. Clinical studies and registry evidence reinforce device safety, long-term durability, and quality-of-life benefits. Procurement teams prioritize platforms supported by strong evidence and predictable outcomes to minimize reintervention costs. Value-based care considerations also favor devices that reduce complications and long-term surveillance burden. As payers and hospitals align on minimally invasive pathways, the market experiences more predictable adoption. This reimbursement and evidence alignment supports stable growth through 2032.

Challenges in the Market

• High Device Cost and Budget Constraints in Hospital Procurement
  Abdominal stent graft systems are high-value implants, and budget constraints in China can limit rapid adoption across smaller hospitals. Advanced devices such as fenestrated and branched platforms increase total procedure cost, requiring clear justification through outcomes and patient eligibility. Procurement decisions often depend on reimbursement adequacy, volume forecasts, and cost containment priorities. Hospitals may standardize to fewer vendors to reduce inventory cost, which can restrict competition for newer entrants. In cost-sensitive environments, device pricing pressure can reduce margins and slow technology adoption. Cost barriers remain one of the most significant constraints for broad-based market expansion.

• Anatomy-Driven Eligibility Limitations and Complex Case Planning Requirements
  Not all AAA patients in China are anatomically suitable for standard EVAR, especially those with short necks, high angulation, or severe calcification. Complex AAA solutions require detailed imaging, precise planning, and specialized physician expertise, which may not be available in all centers. Planning-intensive procedures can increase pre-operative time, device selection complexity, and overall operational burden. Errors in sizing or landing zone planning can raise endoleak and reintervention risk, discouraging low-volume centers from complex cases. Even with improved devices, anatomy constraints remain a limiting factor on addressable patient volume. This anatomical variability is a persistent challenge for market expansion.

• Risk of Endoleaks, Device Migration, and Long-Term Reinterventions
  Endoleaks and related complications remain key concerns in China, requiring ongoing post-implant surveillance and potential reintervention. Long-term outcomes depend on sealing performance, fixation stability, and patient-specific anatomy changes over time. Reinterventions increase total cost of care and can reduce patient satisfaction and hospital performance metrics. Clinicians may prefer established platforms with extensive long-term data, which can slow adoption of newer designs without comparable evidence. Surveillance protocols require imaging follow-up, increasing healthcare system burden and patient compliance requirements. Managing long-term complication risk remains a central clinical and commercial challenge.

• Regulatory Approval Complexity and Extended Qualification Timelines
  Stent graft systems face strict regulatory review in China due to their implantable nature and high-risk classification. Clinical evidence requirements and post-market surveillance obligations increase time-to-market and development cost for manufacturers. Changes in materials, delivery systems, or design geometry may require additional testing and re-approval, slowing iteration cycles. Hospitals and physicians also require training and proctoring, extending the commercialization timeline after approvals. Regulatory variability across regions can increase complexity for suppliers operating multi-market portfolios. These approval and qualification timelines can slow innovation rollout and limit rapid market scaling.

• Operational Dependence on Skilled Teams, Imaging, and Post-Procedure Surveillance
  Successful EVAR programs in China require specialized teams, imaging capability, and structured follow-up protocols, which may not be uniformly available. Hybrid OR availability, endovascular tools, and trained staff are essential for complex repairs and complication management. Post-procedure imaging surveillance is mandatory in many cases, increasing resource use and requiring strong patient adherence. Variability in follow-up can increase complication risk and reduce measured outcomes, impacting adoption confidence in lower-resource settings. Training and retention of skilled personnel can be difficult, especially outside major urban centers. Operational dependency remains a barrier to uniform penetration across China.

China Abdominal Stent Graft System Market Segmentation

By Product Type

• Standard EVAR Stent Grafts

• Fenestrated EVAR Stent Grafts

• Branched EVAR Stent Grafts

By Material

• ePTFE-Based Grafts

• Polyester (Dacron) Based Grafts

By End User

• Hospitals

• Specialty Vascular Centers

• Ambulatory Surgical Centers

By Indication

• Infrarenal AAA

• Juxtarenal AAA

• Complex AAA (Pararenal / Suprarenal)

Leading Key Players

• Medtronic

• W. L. Gore & Associates

• Endologix

• Terumo Aortic

• Cook Medical

• Bentley InnoMed

• Getinge

• BD (Bard Peripheral Vascular legacy products)

Recent Developments

• Medtronic expanded EVAR platform enhancements focused on improved conformability and controlled deployment for complex anatomies in China.

• W. L. Gore & Associates advanced graft material and sealing-zone design strategies aimed at reducing endoleak risk in AAA repair workflows.

• Cook Medical strengthened complex AAA planning and device configuration capabilities to support broader fenestrated adoption in China.

• Terumo Aortic expanded endovascular aneurysm repair system positioning through integrated procedural support and clinician training programs.

• Endologix progressed device optimization initiatives focused on fixation durability and long-term surveillance outcomes in China.

This Market Report Will Answer the Following Questions

1. What is the projected market size and growth rate of the China Abdominal Stent Graft System Market by 2032?

2. Which stent graft types (standard EVAR, fenestrated, branched) are growing fastest in China and why?

3. How are device design improvements reducing endoleaks and expanding eligibility for complex anatomies?

4. What operational, regulatory, and cost barriers most influence adoption across hospitals and vascular centers?

5. Who are the key players shaping competition, clinical evidence, and innovation in the abdominal stent graft system market?